EGFR and neoplasm: Likewise, from the exploratory biomarker analysis of the FAST-ACT II study, Mok TS et al. recently demonstrated that EGFR mutations detected in plasma from patients who received 3 cycles of treatment was predictive for worse PFS and OS37, and was correlated with change in tumor burden or increased metastases.